A Single-Dose, Open-Label, Randomized, Two-Way, Cross-Over Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Healthy Indian Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Dec 2015 Results published in the Clinical Therapeutics
- 18 Dec 2012 New trial record